Fig. 3

DHA executes a transient ROS surge in l(2)gl/l(2)gl mutant to implement anti-tumor effect. Representative figure panel with illustration showing the ROS signals in the dissected brain samples (White arrows indicate some of the quantified regions). The illustration was drawn by Sushree Sulava, the first author of this manuscript using Microsoft Powerpoint (Office 2021). Quantitation of ROS levels in the larval brain in wild-type and tumorous strains with and without drug treatment showed elevated levels of ROS post-DHA treatment on the 8th day in the early third-instar stage of the l(2)gl/l(2)gl mutant, followed by a steep decrease in ROS activity on the 10th day (late third-instar of the l(2)gl/l(2)gl mutant), similar to levels seen on the 7th day for the late third-instar stage of the wild-type larvae (N = 6) (Scale bar: 20 μm) (*p < 0.05, **p < 0.01, and ***p < 0.001).